FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
|Articles|July 13, 2023
Grow and Protect Your Wealth with Private Real Estate
Advertisement
Now, physicians can invest in a diversified private real estate fund designed to deliver passive income and appreciation — while aiming to minimize the impact of taxes.
By targeting U.S. cities and submarkets expected to experience significant rent growth/demand, this investment delivers:
- Tactical portfolio that is intended to be resilient across various market cycles
- 5.8% distribution yield, 68% more than the 10-year Treasury note1
- Tax-efficient, REIT structure2
Download this illustrated, fact-rich overview and take a step toward a better way to protect and grow your wealth.
Complete the form below to download the fund overview.
1) The net distribution yield is as of 3/31/23 and is calculated as the (March 2023 divided by equity invested) divided by the (31 divided by 365 days in the year.) Referenced 10-year Treasury Note is as of 4/13/23.
2) Current federal tax provisions allow for a 20% deduction on taxable REIT dividends of ordinary income through the end of 2025
Sponsored by
Advertisement
Related to this article
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial
3
How Breast Milk Shapes Gut Microbiome Signaling and Immunity
4
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
5